ライフサイエンスコーパス: peripartum

1 Peripartum administration of single-dose nevirapine redu

2 Peripartum ALA supplementation in dairy cows improved sy

3 geometric mean concentrations between their peripartum and follow-up levels for immunoglobulin G to

4 There is a paucity of data on peripartum and long-term clinical outcomes in women with

5 ng treatment thresholds and optimal BP range peripartum and postpartum and evaluating interventions t

6 Strategies to improve the peripartum and postpartum HBV care cascade are urgently

7 The risks of Ebola virus reactivation in the peripartum and postpartum period and of adverse birth ou

8 RBC transfusion to the risks of antepartum, peripartum and postpartum VTE are reported as odds ratio

9 ose vaccination (to 80% of neonates), use of peripartum antivirals (to 80% of hepatitis B e antigen-p

10 induction protocol in multiparous dairy cows peripartum, as well as in vitro via small interfering RN

11 ight be associated with an increased risk of peripartum bleeding, which could be mitigated by discont

12 Although the frequency of peripartum cardiomyopathy (185 of 100,000 deliveries) at

13 e: idiopathic cardiomyopathy (616 patients), peripartum cardiomyopathy (51); and cardiomyopathy due t

14 adjusted OR [aOR], 2.12; 95% CI, 2.07-2.17), peripartum cardiomyopathy (aOR, 4.42; 95% CI, 3.79-5.13)

15 5), hypertrophic cardiomyopathy (n = 40) and peripartum cardiomyopathy (n = 69) for disease-causing P

16 Peripartum cardiomyopathy (PPCM) and dilated cardiomyopa

17 t ventricular (LV) recovery in patients with peripartum cardiomyopathy (PPCM) and to record rates of

18 c shock (CS) is a recognized complication of peripartum cardiomyopathy (PPCM) associated with poor pr

19 The term peripartum cardiomyopathy (PPCM) describes dilated cardi

20 Peripartum cardiomyopathy (PPCM) disproportionately affe

21 bsequent pregnancies (SSPs) in patients with peripartum cardiomyopathy (PPCM) have not been analyzed.

22 The epidemiology of peripartum cardiomyopathy (PPCM) in Europe is poorly und

23 Nigeria has the highest incidence of peripartum cardiomyopathy (PPCM) in the world.

24 Peripartum cardiomyopathy (PPCM) is a disease that occur

25 Peripartum cardiomyopathy (PPCM) is a life-threatening d

26 Peripartum cardiomyopathy (PPCM) is a life-threatening h

27 Peripartum cardiomyopathy (PPCM) is a life-threatening p

28 Peripartum cardiomyopathy (PPCM) is a potentially fatal

29 Peripartum cardiomyopathy (PPCM) is a pregnancy-associat

30 Peripartum cardiomyopathy (PPCM) is a rare life-threaten

31 Peripartum cardiomyopathy (PPCM) is an idiopathic form o

32 Peripartum cardiomyopathy (PPCM) is an often fatal disea

33 Peripartum cardiomyopathy (PPCM) is due to dysregulated

34 Peripartum cardiomyopathy (PPCM) is the unexplained loss

35 this study was to systematically review the peripartum cardiomyopathy (PPCM) literature and determin

36 Peripartum cardiomyopathy (PPCM) remains a major cause o

37 Peripartum cardiomyopathy (PPCM) remains a serious threa

38 psia is a risk factor for the development of peripartum cardiomyopathy (PPCM), but it is unknown whet

39 or in the postpartum period, manifesting as peripartum cardiomyopathy (PPCM).

40 d disruptions in these processes can lead to peripartum cardiomyopathy (PPCM).

41 left ventricular (LV) recovery in women with peripartum cardiomyopathy (PPCM).

42 Black women are at greater risk for peripartum cardiomyopathy (PPCM).

43 imbalance during pregnancy may lead to acute peripartum cardiomyopathy (PPCM).

44 describe the characteristics and outcomes of peripartum cardiomyopathy (PPCMP) patients who received

45 ) 1.37 (95% confidence interval 1.27-1.47)], peripartum cardiomyopathy [aOR 2.10 (1.11-3.99)], and ar

46 verexpression of Galpha(q) exhibit a lethal, peripartum cardiomyopathy accompanied by apoptosis.

47 have also been linked to conditions such as peripartum cardiomyopathy and chemotherapy-induced cardi

48 A comparison between the peripartum cardiomyopathy and early pregnancy-associated

49 rdiology, we identified 44 women who had had peripartum cardiomyopathy and had a total of 60 subseque

50 action <45%) is crucial for the diagnosis of peripartum cardiomyopathy and the exclusion of other cau

51 She was diagnosed with peripartum cardiomyopathy and treatment with digoxin and

52 Patients with peripartum cardiomyopathy appear to have a better progno

53 Anthracycline-associated cardiomyopathy and peripartum cardiomyopathy are nonischemic cardiomyopathi

54 This Seminar summarises current knowledge of peripartum cardiomyopathy genetics, pathophysiology, dia

55 idiopathic cardiomyopathy, the patients with peripartum cardiomyopathy had better survival (adjusted

56 For decades, peripartum cardiomyopathy has remained an enigma.

57 Peripartum cardiomyopathy has variable disease progressi

58 Mortality rates in peripartum cardiomyopathy have decreased, and this is mo

59 mation has also indicated that many cases of peripartum cardiomyopathy have genetic underpinnings.

60 Conversely, sNix protected against apoptotic peripartum cardiomyopathy in G(alpha)q-overexpressors.

61 view are to describe the clinical profile of peripartum cardiomyopathy in the United States and to pr

62 Peripartum cardiomyopathy is a cardiomyopathy of unknown

63 Peripartum cardiomyopathy is a disease with considerable

64 Peripartum cardiomyopathy is a form of systolic heart fa

65 Peripartum cardiomyopathy is a heart disease of unknown

66 Peripartum cardiomyopathy is a potentially life-threaten

67 Peripartum cardiomyopathy is a pregnancy-associated myoc

68 Peripartum cardiomyopathy is a rare and sometimes fatal

69 Peripartum cardiomyopathy is a rare complication of preg

70 Peripartum cardiomyopathy is a rare lethal disease about

71 sequent pregnancy in women with a history of peripartum cardiomyopathy is associated with a significa

72 search in the past decade has suggested that peripartum cardiomyopathy is caused by vascular dysfunct

73 Peripartum cardiomyopathy is increasingly recognised and

74 Management of peripartum cardiomyopathy is largely limited to the same

75 Although peripartum cardiomyopathy is the most common diagnosis f

76 hy and myocarditis, but its effectiveness in peripartum cardiomyopathy is unknown.

77 cular function and survival in the Galpha(q) peripartum cardiomyopathy model.

78 Peripartum cardiomyopathy occurs globally in all ethnic

79 Based on clinical observations of peripartum cardiomyopathy patients and the high rate of

80 Peripartum cardiomyopathy patients from the EORP PPCM re

81 Peripartum cardiomyopathy patients had a high incidence

82 Peripartum cardiomyopathy patients had a mean age of 31+

83 For >50% of peripartum cardiomyopathy patients, left ventricular fun

84 r-specific antibodies (n=69, 57%), and prior peripartum cardiomyopathy pretransplant (n=57, 47%).

85 Peripartum cardiomyopathy seems to affect women in diffe

86 omen had a 15.7-fold higher relative risk of peripartum cardiomyopathy than non-African Americans (od

87 men have significantly higher odds of having peripartum cardiomyopathy that could not be explained by

88 tutes of Health (NIH) convened a Workshop on Peripartum Cardiomyopathy to foster a systematic review

89 ared the clinical outcomes of six women with peripartum cardiomyopathy treated with intravenous immun

90 The frequency of peripartum cardiomyopathy varies markedly between Africa

91 U.S. studies confirmed that the frequency of peripartum cardiomyopathy was significantly higher among

92 icity remained a significant risk factor for peripartum cardiomyopathy when other risk factors were c

93 Given the poor prognosis of women with peripartum cardiomyopathy who do not improve, this thera

94 thy was a prospective 30-center study of 100 peripartum cardiomyopathy women with LV ejection fractio

95 igeria has the highest reported incidence of peripartum cardiomyopathy worldwide.

96 Primary study end points were preeclampsia, peripartum cardiomyopathy, and heart failure.

97 ons with RA had higher risk of preeclampsia, peripartum cardiomyopathy, arrhythmias, acute kidney inj

98 gy, clinical presentation, and management of peripartum cardiomyopathy, as well as the current knowle

99 shed from 1966 to July 1999, using the terms peripartum cardiomyopathy, cardiomyopathy, and pregnancy

100 sk of complications, including preeclampsia, peripartum cardiomyopathy, heart failure, arrhythmias, A

101 de spectrum of cardiomyopathies that include peripartum cardiomyopathy, hypertrophic cardiomyopathy,

102 this small retrospective study of women with peripartum cardiomyopathy, patients treated with immune

103 ons of pregnancy, including preeclampsia and peripartum cardiomyopathy, with a focus on pathological

104 imilar to those of patients with traditional peripartum cardiomyopathy.

105 entricular function in women presenting with peripartum cardiomyopathy.

106 erican women are at increased risk of having peripartum cardiomyopathy.

107 ne hundred women met traditional criteria of peripartum cardiomyopathy; 23 were diagnosed with pregna

108 d an independent risk factor associated with peripartum cardiovascular complications, including preec

109 R) for the association between SLE and acute peripartum cardiovascular complications.

110 r promptly recognize and treat patients with peripartum cardiovascular decompensation.

111 nesthesiology approach to patients with high peripartum cardiovascular risk and ensuring that cardio-

112 a, we estimated the rate of HBV MTCT and the peripartum care cascade among pregnant women.

113 ity is attenuated with expert anesthesiology peripartum care, which includes the management of neurax

114 Women with detectable peripartum CMV viruria were more likely to have infants

115 to help predict PAS, placenta percreta, and peripartum complications and for comparison of the area

116 ortion facility, and then excess deaths (and peripartum complications) from forcing these unwanted pr

117 of deaths caused by infectious diseases and peripartum complications, declining total and adolescent

118 0.81; 95% CI: 0.73, 0.89; P < .001) and with peripartum complications, including massive bleeding (AU

119 Despite the lack of catastrophic peripartum complications, the prevalence of both aortic

120 ater was predictive of placenta percreta and peripartum complications.

121 al vessel (IFV) diameter at MRI with PAS and peripartum complications.

122 Whereas peripartum congenital measles is severe, asymptomatic me

123 necessitates a multidisciplinary approach to peripartum counseling and surveillance.

124 , RA remained an independent risk factor for peripartum CV complications including preeclampsia [adju

125 yndrome is a prevalent metabolic disorder in peripartum dairy cows that unfavorably impacts lactation

126 abundance and liver triglyceride content in peripartum dairy cows, while adipose PNPLA3 protein abun

127 h (OR 1.62, 95% CI 1.14 to 2.30, p = 0.007), peripartum depression (OR 2.20, 95% CI 1.04 to 4.65, p =

128 the changes in brain networks implicated in peripartum depression (PPD).

129 sorder (MDD)] and GABAergic (brexanolone for peripartum depression) systems have become available.

130 nset depression), sex differences (including peripartum depression), and response to treatment.

131 one are implicated in the pathophysiology of peripartum depressive symptoms (PDS).

132 ned formula-fed infants born to women with a peripartum diagnosis of HIV type 1 (HIV-1) infection to

133 isorders of pregnancy, gestational diabetes, peripartum dissection, polycystic ovarian syndrome, etc.

134 eviously been randomly assigned to a single, peripartum dose of nevirapine or placebo in a trial in B

135 d within 6 months after receipt of a single, peripartum dose of nevirapine.

136 to model MOUD, or oxycodone (OXY), to model peripartum drug use, before, during, and after pregnancy

137 We found that peripartum exposure to 20 mg/kg fluoxetine reduced femor

138 t diagnosis of acute pulmonary embolism in a peripartum female patient, the multidisciplinary approac

139 disorder in women that might be triggered by peripartum fluctuations in reproductive hormones.

140 We hypothesized that peripartum GABAergic neuroactive steroids (NAS) are rela

141 at of high-income countries and is driven by peripartum haemorrhage and anaesthesia complications.

142 appropriate management of mothers at risk of peripartum haemorrhage might improve maternal and neonat

143 hlorodiphenyldichloroethylene), and maternal peripartum hair mercury (Hg) levels were measured to est

144 Better understanding of the peripartum HCV care cascade at the population level is n

145 n of antepartum admission, and antepartum or peripartum hemorrhage.

146 enta accreta is one of the leading causes of peripartum hemorrhage.

147 and to examine a modern approach to massive peripartum hemorrhage.

148 viruses were associated with reduced risk of peripartum HIV infection in the historic U.S. Woman and

149 stered soon after birth, before in utero and peripartum HIV infection is excluded.

150 cific IgG antibodies associated with reduced peripartum HIV transmission risk in this cohort.

151 m regimens, was not associated with in utero/peripartum HIV transmission.

152 coronavirus 2 (SARS-CoV-2) infections during peripartum hospitalizations is important to guide care,

153 italizations during which pregnancies ended (peripartum hospitalizations) among a cohort of pregnant

154 of knowledge of diagnosis, and insufficient peripartum imaging data.

155 e hippocampus and amygdala change during the peripartum in relation to childbirth experience and peri

156 This indicates maternal peripartum infection is an important complication of chi

157 ve strategies for preventing and controlling peripartum infection should be an obstetrical priority.

158 ate the average global incidence of maternal peripartum infection.

159 is, and 1.1% (95% CI 0.3%-2.4%) for maternal peripartum infection.

160 ing cause of neonatal sepsis and meningitis, peripartum infections in women, and invasive infections

161 Whether peripartum insufficiencies in brain oxygenation, known a

162 Median peripartum maternal log2 sCD14 concentration was higher

163 ative polymerase chain reaction) measured in peripartum maternal plasma; 161 (33%) were anti-HCV-posi

164 ity (aOR: 1.33; 95% CI: 1.08-1.64) (site 2), peripartum Medicaid coverage (aOR: 1.33; 95% CI: 1.06-1.

165 g, and largely prevented lethality in the Gq peripartum model of apoptotic cardiomyopathy.

166 er, the efficacy and safety of psilocybin in peripartum mood disorders has not been investigated.

167 connect, anxiety, and blunted affect seen in peripartum mood disorders.

168 cular therapies will contribute to improving peripartum morbidity and mortality.

169 ctively, and hundreds of additional cases of peripartum morbidity.

170 Despite significant progress in reducing peripartum mother-to-child transmission (MTCT) of human

171 Despite significant progress in reducing peripartum MTCT of HIV with ART, continued access to ART

172 responses; thus, we examined the effects of peripartum n-3 on systemic and adipose tissue (AT)-speci

173 Peripartum n-3 reduced the plasma concentrations of Inte

174 her, these results provide novel evidence of peripartum neuroimmune alterations following chronic opi

175 To test this, we recapitulated the peripartum neuroimmune profile by depleting microglia in

176 story of DSM-5 major depressive episode with peripartum onset (n = 15) or parous healthy controls wit

177 rodent model to assess the impact of chronic peripartum opioid exposure or MOUD on maternal caregivin

178 Peripartum or postpartum SHIV infection (n = 3) resulted

179 ly associated with increased risk of adverse peripartum outcomes.

180 addressing racial and ethnic disparities in peripartum pain assessment and treatment is a national p

181 y risk factors for mortality in pregnant and peripartum patients receiving extracorporeal membrane ox

182 There were 280 peripartum patients who received extracorporeal membrane

183 s of this multicenter database, pregnant and peripartum patients with refractory cardiac or respirato

184 ncy of seizures during pregnancy through the peripartum period (the first 6 weeks after birth) (epoch

185 verse maternal and offspring outcomes in the peripartum period and in the long term.

186 ociated disease that typically arises in the peripartum period and is marked by left ventricular dysf

187 Mothers infected in the peripartum period appear to not only passively protect t

188 myopathy of unknown cause that occurs in the peripartum period in previously healthy women.

189 The peripartum period is accompanied by numerous physiologic

190 The peripartum period is accompanied by peripheral immune al

191 In patients with PPCM, the peripartum period is associated with profound and rapid

192 iomyocytes induced by multiple miRNAs in the peripartum period may be crucial in PPCM pathophysiology

193 eriment, we administered estrogen during the peripartum period to determine if estrogen supplementati

194 re than 5 months after delivery (outside the peripartum period) up to 34 years 7 months.

195 y and safety of lithium treatment during the peripartum period, focusing on women with bipolar disord

196 ood provides an initial challenge during the peripartum period, requiring continuous adaptation; yet

197 rom uninfected dams, particularly during the peripartum period, suggesting that close contact during

198 Therefore, the peripartum period, which includes the period before (pre

199 third of CMV infections occurred during the peripartum period, with 40% acquired through breastfeedi

200 nd the impact of medications used during the peripartum period.

201 in dissection risk was observed outside the peripartum period.

202 cyte apoptosis was not suppressed during the peripartum period.

203 e-threatening heart failure occurring in the peripartum period.

204 high degree of suspicion, especially in the peripartum period.

205 op strategies tailored for each stage in the peripartum period.

206 omeostasis and steroid metabolism during the peripartum period.

207 increased risk of cardiomyopathy during the peripartum period.

208 and quantitative HBsAg were measured in the peripartum period.

209 CRF contributes to maladaptations during the peripartum period.

210 by excess anti-angiogenic signalling in the peripartum period.

211 circulating concentrations of calcium in the peripartum period; however, we surprisingly observed a d

212 the risk of cardiac events during different peripartum periods.

213 Participants included peripartum persons with positive depression screen resul

214 anagement following depression screening for peripartum persons.

215 oning of both fetal development and maternal peripartum physiology.

216 and occipital cortices (OCC) and quantified peripartum plasma NAS.

217 studies with a small (n<100), pediatric, or peripartum population.

218 rectly limit liver triglyceride accumulation peripartum, potentially preventing bovine fatty liver or

219 als with secondary cardiomyopathies, such as peripartum (PPCM), alcohol-induced (ACM), and cancer the

220 and should be suspected in any women who are peripartum presenting with symptoms and signs indicative

221 The first study was on peripartum prevalence of Paenibacillus in mother-newborn

222 ose colonized with GBS and administration of peripartum prophylaxis to those identified as carriers t

223 ole in recognizing the signs and symptoms of peripartum psychiatric disorders, particularly postpartu

224 e higher risk of pregnancy complications and peripartum psychiatric problems than in women without ep

225 Peripartum QFT-Plus positivity was stable and less influ

226 regnancy and the postpartum period to reduce peripartum relapse risk.

227 Peripartum respiratory infections may be underrecognized

228 , increasing the dietary supply of ME and MP peripartum resulted in greater milk production, stimulat

229 Factors associated with higher peripartum SARS-CoV-2 testing odds were Asian race (adju

230 17 858 pregnant persons, 10 863 (60.8%) had peripartum SARS-CoV-2 testing; 222/10 683 (2.0%) had pos

231 , extracoronary fibromuscular dysplasia, and peripartum SCAD were independent predictors of long-term

232 Presence of genetic disorders, peripartum SCAD, and extracoronary fibromuscular dysplas

233 SCAD phenotype were selected and defined as peripartum SCAD, recurrent SCAD, or SCAD in an individua

234 t testing identified novel associations with peripartum SCAD.

235 This peripartum screening approach might be used to identify

236 study sought to assess the effectiveness of peripartum screening in predicting CHT after HDP.

237 We measured maternal peripartum serum DDT and urine pyrethroid metabolite con

238 In women with prior exposure to peripartum single-dose nevirapine (but not in those with

239 x 2 factorial randomized clinical trial with peripartum (single-dose nevirapine vs placebo) and postp

240 sed intervention with financial incentive on peripartum smoking among pregnant individuals.

241 and breastfeeding women, yet the effects of peripartum SSRI exposure on neonatal bone are not known.

242 no study to date has examined the effects of peripartum SSRIs on long bone growth or mass.

243 Depending on these risks and peripartum stage, the benefits of thromboprophylaxis can

244 9% (56.4% in those with complete screening), peripartum state 4.5%, and genetic disorders 1.6%.

245 Eligibility included (i) a peripartum state, (ii) signs or symptoms of heart failur

246 ng, migraine, acute or chronic hypertension, peripartum state, or use of serotonergic drugs with clin

247 essential to protect the maternal heart from peripartum stress.

248 th available VL results, the overall rate of peripartum suppression was 82%, and undetectable viremia

249 ERK signaling is cardioprotective during the peripartum term.

250 ighlight potential disparities in SARS-CoV-2 peripartum testing by demographic and pregnancy characte

251 The use of heterogenous peripartum time points, study cohorts, depression sympto

252 Manipulating maternal respiratory flora peripartum to influence the infant microbiome has not pr

253 1%), with in utero transmission in 21 (36%), peripartum transmission in 26 (45%), and transmission vi

254 V-1 strains also predicted a reduced risk of peripartum transmission in secondary analyses.

255 ncy virus (HIV) load is paramount to prevent peripartum transmission in women diagnosed late in pregn

256 on of HIV viral load is paramount to prevent peripartum transmission in women diagnosed late in pregn

257 Although neonatal sepsis due to the peripartum transmission of S. pneumoniae is rare, this c

258 ct with its central role in heterosexual and peripartum transmission, has important implications for

259 prospective study, women with HDP underwent peripartum transthoracic echocardiography and were evalu

260 ely than their White counterparts to undergo peripartum urine drug screening (UDS) and subsequent rep

261 Peripartum variations in MIS type II receptor expression

262 Correlates of peripartum virologic suppression and undetectable viremi

263 antiretroviral therapy (ART) and the rate of peripartum virologic suppression in a large prevention o

264 The main outcome measure was the rate of peripartum virologic suppression, defined as viral load

265 increases in depression symptoms during the peripartum were positively correlated with changes in th

266 Cows were supplemented peripartum with saturated fat (CTL) or flaxseed suppleme

267 migration (i.e., change in residency) among peripartum women from rural South Africa and their assoc

268 ndings suggest that financial hardship among peripartum women in the United States was common from 20

269 tudy, we found that a substantial portion of peripartum women moved within the country around the tim

270 ethnic groups and should be suspected in any peripartum women presenting with symptoms and signs of h

271 2013 to 2018, 24.2% (95% CI, 22.6%-26.0%) of peripartum women reported unmet health care need, 60.0%

272 In this study, we observed that HIV-positive peripartum women who externally migrated and delivered o

273 Peripartum women with household incomes less than 400% o

274 CIPANTS: This cross-sectional study included peripartum women, defined as women aged 18 to 45 years w

275 Signs of severe sepsis in peripartum women, particularly with confirmed or suspect

276 The study cohort included 3509 peripartum women, weighted to represent 1 050 789 women,

277 rgeted interventions for mobile HIV-positive peripartum women.

278 e guidelines are applied in the treatment of peripartum women.

279 health care access and health outcomes among peripartum women.

280 Plus had higher diagnostic yield than TST in peripartum women.

281 and promote overall economic security among peripartum women.

282 l II, and Mortality Probability Model III in peripartum women.